Metharbital

Summary

Metharbital (CHEMBL450) is an approved small molecule (ATC N03AA30); indicated across 1 condition including epilepsy.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N03AA30
• Indications: 1 condition
• Chemistry: 198.22 Da · C9H14N2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL450
Name	Metharbital
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4099
ATC	N03AA30
Molecular formula	C9H14N2O3
Molecular weight	198.22
InChIKey	FWJKNZONDWOGMI-UHFFFAOYSA-N

SMILES: CCC1(C(=O)NC(=O)N(C1=O)C)CC

IUPAC name: 5,5-diethyl-1-methyl-1,3-diazinane-2,4,6-trione

Also known as: Gemonil, Metarbital, Metharbital, Metharbital ciii, Metharbitone, NSC-27156, METHARBITAL, SID144206305, metharbital

Patent coverage: 1,147 distinct patent families (5,035 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,026 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
epilepsy	4	MONDO:0005027	EFO:0000474

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).